Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H13N3O5 |
| Molecular Weight | 243.217 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cn([C@@]2([H])[C@]([H])([C@@]([H])([C@@]([H])(CO)O2)O)O)c(nc1=N)O
InChI
InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
| Molecular Formula | C9H13N3O5 |
| Molecular Weight | 243.217 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdfCurator's Comment:: Description was created using several sources including:
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680
http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment:: Description was created using several sources including:
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680
http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330
Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.
CNS Activity
Originator
Curator's Comment:: Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley. It was approved by the United States Food and Drug Administration in June 1969, and was initially marketed in the U.S. by Upjohn under the trade name Cytosar-U and is at present manufactured by Pfizer, Sicor Pharmaceuticals and Teva. CYTOSAR (cytarabine injection) was developed in September 1994 Dana-Farber Cancer Institute and is manufactured by Pfizer and Perrigo. DEPOCYT - (cytarabine injection, lipid complex) manufactured by Manufactured by: Pacira Pharmaceuticals Inc., distributed by Sigma-Tau Pharmaceutical, Inc. is an intrathecal cancer chemotherapeutic agent approved by FDA is used for the treatment of lymphomatous meningitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5367 Sources: http://www.drugbank.ca/drugs/DB00987 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf |
Primary | CYTARABINE Approved UseCytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia. Launch Date-1.71072E10 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
62.2 μg/mL |
100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN |
CYTARABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1900 μg × h/mL |
100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN |
CYTARABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40.4 h |
100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN |
CYTARABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
80 h |
50 mg single, intrathecal dose: 50 mg route of administration: Intrathecal experiment type: SINGLE co-administered: |
CYTARABINE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: Page: p.363, 366 |
unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: Page: p.363, 366 |
Disc. AE: Cerebellar disorder NOS, Diarrhea... AEs leading to discontinuation/dose reduction: Cerebellar disorder NOS (grade 4, 66.7%) Sources: Page: p.363, 366Diarrhea (grade 3, 66.7%) |
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: Page: p.2578 |
unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: Page: p.2578 |
Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS... AEs leading to discontinuation/dose reduction: Cerebellar disorder NOS (grade 4, 33.3%) Sources: Page: p.2578Cerebellar disorder NOS (grade 5, 16.7%) |
3 g/m2 2 times / day multiple, intravenous MTD Dose: 3 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 3 g/m2, 2 times / day Sources: Page: p.366 |
unhealthy, 16-76 n = 27 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 27 Sources: Page: p.366 |
|
100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
Disc. AE: Bone marrow depression, Leukopenia... AEs leading to discontinuation/dose reduction: Bone marrow depression Sources: Page: p.1Leukopenia Thrombocytopenia Anemia Nausea Vomiting Diarrhea Abdominal pain Oral ulceration Hepatic dysfunction NOS |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Diarrhea | grade 3, 66.7% Disc. AE |
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: Page: p.363, 366 |
unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: Page: p.363, 366 |
| Cerebellar disorder NOS | grade 4, 66.7% Disc. AE |
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: Page: p.363, 366 |
unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: Page: p.363, 366 |
| Cerebellar disorder NOS | grade 4, 33.3% Disc. AE |
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: Page: p.2578 |
unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: Page: p.2578 |
| Cerebellar disorder NOS | grade 5, 16.7% Disc. AE |
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: Page: p.2578 |
unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: Page: p.2578 |
| Abdominal pain | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Anemia | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Bone marrow depression | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Diarrhea | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Hepatic dysfunction NOS | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Leukopenia | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Nausea | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Oral ulceration | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Thrombocytopenia | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
| Vomiting | Disc. AE | 100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: Page: p.1 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 4.0 |
yes [IC50 6.6 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 4.0 |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. | 2000 Jul |
|
| Visual loss following high-dose cytosine arabinoside (ARA-C). | 2000 Mar |
|
| Misdiagnosis of broad-complex tachycardia. | 2000 Nov-Dec |
|
| Heterotopia in microcephaly induced by cytosine arabinoside: hippocampus in the neocortex. | 2000 Oct |
|
| Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. | 2000 Sep |
|
| Treatment for primary CNS lymphoma: the next step. | 2000 Sep |
|
| Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis. | 2001 Apr |
|
| Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. | 2001 Apr |
|
| The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway. | 2001 Apr 1 |
|
| Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. | 2001 Apr 1 |
|
| Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells. | 2001 Apr 15 |
|
| Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia. | 2001 Apr-May |
|
| [Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C]. | 2001 Feb |
|
| Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone. | 2001 Feb |
|
| Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. | 2001 Feb |
|
| Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism. | 2001 Feb |
|
| Bilateral breast relapse in acute myelogenous leukemia. | 2001 Feb |
|
| Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. | 2001 Feb |
|
| [Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?]. | 2001 Feb |
|
| Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. | 2001 Feb |
|
| Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect. | 2001 Feb 15 |
|
| Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. | 2001 Feb 15 |
|
| Topoisomerase II inhibitor induced leukemia in a patient with AIDS. | 2001 Feb 16 |
|
| Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. | 2001 Feb 2 |
|
| Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents. | 2001 Feb 20 |
|
| [Palpable mantel cell lymphoma in the breast]. | 2001 Feb 3 |
|
| Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. | 2001 Jan |
|
| Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. | 2001 Jan |
|
| Aseptic meningitis in a child after systemic treatment with high dose cytarabine. | 2001 Jan |
|
| A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. | 2001 Jan |
|
| Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. | 2001 Jan |
|
| Acute progranulocytic leukemia. | 2001 Jan |
|
| Chemotherapy and marrow transplantation for congenital leukaemia. | 2001 Jan |
|
| Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine. | 2001 Jan 1 |
|
| Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment. | 2001 Jan 1 |
|
| Porcine Choroid plexus epithelial cells in culture: regulation of barrier properties and transport processes. | 2001 Jan 1 |
|
| Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. | 2001 Jan 15 |
|
| JP-8 jet fuel-induced DNA damage in H4IIE rat hepatoma cells. | 2001 Jan 25 |
|
| Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons. | 2001 Jan 31 |
|
| The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study. | 2001 Jan-Feb |
|
| Therapy of acute myeloid leukemia. | 2001 Jan-Feb |
|
| Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. | 2001 Mar |
|
| Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials. | 2001 Mar |
|
| Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia. | 2001 Mar |
|
| Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity? | 2001 Mar |
|
| Severe hepatic injury associated with lipid formulations of amphotericin B. | 2001 Mar 1 |
|
| Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. | 2001 Mar 15 |
|
| Total body irradiation before allogeneic bone marrow transplantation: is more dose better? | 2001 Mar 15 |
|
| Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML. | 2001 Mar 2 |
Sample Use Guides
Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3).
Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13.
Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Route of Administration:
Intratracheal
In Vitro Use Guide
Curator's Comment:: The effect of Ara-C (0.1 μM) treatment on HUVEC proliferation alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:58:26 UTC 2021
by
admin
on
Fri Jun 25 20:58:26 UTC 2021
|
| Record UNII |
04079A1RDZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
L01XY01
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
FDA ORPHAN DRUG |
234806
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
NDF-RT |
N0000175595
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
NDF-RT |
N0000000233
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DEPOCYT (AUTHORIZED: MENINGEAL NEOPLASMS)
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
FDA ORPHAN DRUG |
265808
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
NCI_THESAURUS |
C1557
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
FDA ORPHAN DRUG |
73393
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
LIVERTOX |
254
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
WHO-ATC |
L01BC01
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/11/942
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
||
|
WHO-VATC |
QL01BC01
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
968804
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
ALTERNATIVE | |||
|
205-705-9
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
147-94-4
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
DB00987
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
SUB06880MIG
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
C408
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
3041
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
M4051
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | Merck Index | ||
|
6253
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
CYTARABINE
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
1162002
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | USP-RS | ||
|
CHEMBL803
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
04079A1RDZ
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
4827
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
770
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
147-94-4
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
D003561
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
1709
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY | |||
|
3049
Created by
admin on Fri Jun 25 20:58:26 UTC 2021 , Edited by admin on Fri Jun 25 20:58:26 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
kcat
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Km
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE ACTIVE -> PARENT |
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
Produced via Cytidine deaminase exposure.
PLASMA
|
||
|
|
METABOLITE ACTIVE -> PARENT | |||
|
|
METABOLITE ACTIVE -> PARENT |
PLASMA
|
||
|
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT | |||
|
|
IMPURITY -> PARENT | |||
|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||